Archives of Virology

, Volume 163, Issue 3, pp 725–730 | Cite as

A comparison of the MeltPro® HPV Test with the Cobas® HPV Test for detecting and genotyping 14 high-risk human papillomavirus types

Brief Report


The clinical performance of the newly developed MeltPro® HPV Test, based on multicolor melting curve analysis, was evaluated and compared with the commercially available Cobas® HPV Test for detection of HPV and genotyping of HPV-16 and HPV-18. A total of 1647 cervical samples were analyzed with both tests. The agreement values were 96.2% for HPV detection, 99.6% for HPV-16 identification, and 99.7% for HPV-18 identification. All genotyping results from MeltPro® HPV Test showed that HPV-52, HPV-58, and HPV-16 were the most common types in this study. Intra-laboratory reproducibility studies showed 97.8% agreement while inter-laboratory reproducibility studies showed 96.9% agreement for the MeltPro® HPV Test. The MeltPro® HPV Test and Cobas® HPV Test are highly correlative and are useful for monitoring HPV infection.



We thank National Natural Science Foundation (81401724 to Y. Liao), Key Project of Cooperation Program for University and Industry of Fujian Province (2013Y4008 to Y. Xu) and Cooperation Program for University and Industry of Xiamen City (3502Z20173013 to Y. Liao) for financial support.

Compliance with ethical standards

Conflict of interest

Q. Li holds equity interest in Zeesan Biotech. All of other authors declare that they have no conflict of interest. The MeltPro® HPV test reagents were kindly provided by Zeesan Biotech.

Humam/animal rights statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

705_2017_3645_MOESM1_ESM.pdf (282 kb)
Supplementary material 1 (PDF 282 kb)


  1. 1.
    Woodman CBJ, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7:11–22CrossRefPubMedGoogle Scholar
  2. 2.
    Henry CK, Maribel A, Claire T, Paula W, Alexandra S, Boyka S, Clare G, Helene B, Christopher R, Robin D, Mina D, Jean M, Andrew B, Andrew T, Sue M, Julian P (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol 10:672–682CrossRefGoogle Scholar
  3. 3.
    World Health Organization (2010) Human papillomavirus laboratory manua. Section 5:35–63Google Scholar
  4. 4.
    Roden R, Wu TC (2006) How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6:753–763CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348:518–527CrossRefPubMedGoogle Scholar
  6. 6.
    Lörincz AT (1996) Hybrid Capture™ method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 22:629–636CrossRefPubMedGoogle Scholar
  7. 7.
    Gravitt P, Peyton C, Apple R, Wheeler C (1998) Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a singlehybridization, reverse line blot detection method. J. Clin. Microbiol 36:3020–3027PubMedPubMedCentralGoogle Scholar
  8. 8.
    Kleter B, Van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, Ter Schegget J, Lindeman J, Harmsel BT, Burger M, Quint W (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37:2508–2517PubMedPubMedCentralGoogle Scholar
  9. 9.
    Liu SS, Leung RCY, Chan KKL, Cheung ANY, Ngan HYS (2010) Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche linear array HPV genotyping assay. J Clin Microbiol 48:758–764CrossRefPubMedGoogle Scholar
  10. 10.
    Heideman D, Hesselink A, Berkhof J, van Kemenade F, Melchers W, Daalmeijer NF, Verkuijten M, Meijer CJLM, Snijders PJF (2011) Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 49:3983–3985CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter WP, Lyons D, Szarewski A (2010) Performance of the Abbott real time high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 82:1186–1191CrossRefPubMedGoogle Scholar
  12. 12.
    Hwang Y, Lee M (2012) Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott real time high risk human papillomavirus test, and the hybrid capture human papillomavirus DNA test for the detection of human papillomavirus. Ann Lab Med 32:201–205CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE (2012) High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. Clin Chem Lab Med 50:655–661CrossRefGoogle Scholar
  14. 14.
    Liao Y, Zhou Y, Guo Q, Xie X, Luo E, Li J, Li Q (2013) Simultaneous detection, genotyping, and quantification of human papillomaviruses by multicolor real-time PCR and melting curve analysis. J Clin Microbiol 51:429–435CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, Pawlita M, Geraets D, Heard I, Gheit T, Tommasino M, Poljak M, Bonde J, Quint W (2016) VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol 76:S14–S21CrossRefPubMedGoogle Scholar
  16. 16.
    Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M (2014) Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol 52:3996–4002CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M (2015) Clinical and analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol 53:3272–3279CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M (2016) Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. J Clin Virol 81:6–11CrossRefPubMedGoogle Scholar
  19. 19.
    Shixuan H, Irina A, Beth AM, Anna MB (1997) Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 70:408–411CrossRefGoogle Scholar
  20. 20.
    Shuang L, Xiao C, Min L, Fengxia C, Liang M, Yongtong C (2015) Distribution of high-risk human papillomavirus genotypes in HPV-infected women in Beijing, China. J Med Virol 87:504–507CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Zhongshan HospitalXiamen UniversityXiamenChina
  2. 2.The State Key Laboratory of Cellular Stress Biology, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Engineering Research Center of Molecular Diagnostics of the Ministry of Education, School of Life SciencesXiamen UniversityXiamenChina
  3. 3.Zeesan Biotechnology CompanyXiamenChina
  4. 4.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, State Key Laboratory of Cellular Stress Biology, Engineering Research Center of Molecular Diagnostics of the Ministry of Education, School of Public HealthXiamen UniversityXiamenChina

Personalised recommendations